Treace Medical Concepts (TMCI) Gains from Sales and Divestitures (2022 - 2026)

Treace Medical Concepts has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $898014.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 79.76% year-over-year to $898014.0; the trailing twelve-month figure through Mar 2026 stood at $898014.0 (up 79.76% YoY), and the FY2025 full-year result was $1.3 million, up 274.27% from the prior year.
• Gains from Sales and Divestitures for Q1 2026 stood at $898014.0, down from $1.3 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $1.3 million in Q4 2025, with the low at $6223.0 in Q4 2022.
• Historically, Gains from Sales and Divestitures has averaged $529299.3 across 5 years, with a median of $420792.0 in 2024.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures soared 2309.11% — and 2026, when it surged 79.76%.
• Treace Medical Concepts' Gains from Sales and Divestitures stood at $6223.0 in 2022, then soared by 2309.11% to $149919.0 in 2023, then soared by 128.13% to $342012.0 in 2024, then surged by 274.27% to $1.3 million in 2025, then decreased by 29.85% to $898014.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $898014.0 (Q1 2026), $1.3 million (Q4 2025), and $499572.0 (Q1 2025), per Business Quant data.